Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.64 |
| ▸ | IKZF2 | Q9UKS7 | 9/20 | 0.56 |
| ▸ | WIZ | O95785 | 1/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30903865 | 0.91 | CRBN (0.69) | CRBNIKZF2WIZCSNK1A1 | |
| SCHEMBL29158021 | 0.91 | CRBN (0.69) | CRBNIKZF2WIZCSNK1A1 | |
| SCHEMBL24207034 | 0.91 | CRBN (0.69) | CRBNIKZF2WIZCSNK1A1 | |
| SCHEMBL26461482 | 0.90 | CRBN (0.65) | CRBNIKZF2WIZCSNK1A1 | |
| SCHEMBL22511606 | 0.90 | CRBN (0.65) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL20128677 | 0.90 | CRBN (0.65) | CRBNIKZF2WIZCSNK1A1 | |
| SCHEMBL30903866 | 0.90 | CRBN (0.67) | CRBNIKZF2WIZCSNK1A1 | |
| SCHEMBL20231556 | 0.89 | CRBN (0.67) | CRBNIKZF2WIZCSNK1A1 | |
| SCHEMBL30635251 | 0.89 | CRBN (0.67) | CRBNIKZF2WIZCSNK1A1 | |
| SCHEMBL25582530 | 0.89 | CRBN (0.64) | CRBNIKZF2WIZCSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-3689868-B1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2023-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | CRBN 3/4885IKZF2 3022/4885WIZ 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.